Vaxcyte Data Highlight Best-in-Class Potential of 24-Valent Pneumococcal Conjugate Vaccine Candidate

  In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied --

-- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards --

-- Results Confirm Potential of Carrier-Sparing, Cell-Free Platform Technology Underlying VAX-24 --

-- Topline Data from the VAX-24 Phase 3 Pivotal Non-Inferiority Study in Adults Expected in 2025 --

https://www.globenewswire.com/news-release/2023/12/04/2790538/0/en/VAX-24-Phase-1-2-Adult-Proof-of-Concept-Data-Published-in-The-Lancet-Infectious-Diseases-Highlight-Best-in-Class-Potential-of-Vaxcyte-s-24-Valent-Pneumococcal-Conjugate-Vaccine-PCV.html